Cargando…

P844: CHARACTERIZATION OF MULTIPLE MYELOMA CELL LINES WITH ACQUIRED-RESISTANCE TO PROTEASOME INHIBITORS HIGHLIGHTS A LINK BETWEEN RESISTANCE AND METABOLIC DEREGULATION

Detalles Bibliográficos
Autores principales:	De Boussac, H., Machura, A., Steer, A., Kassambara, A., Gely, M., Chemlal, D., Gourzones, C., Requirand, G., Robert, N., Vincent, L., Herbaux, C., Bruyer, A., Moreaux, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430562/ http://dx.doi.org/10.1097/01.HS9.0000846260.96341.8f

Ejemplares similares

P843: METABOLOMIC CHARACTERIZATION OF HUMAN MULTIPLE MYELOMA CELL LINE TO STUDY TUMOR RESISTANCE TO DIFFERENT CLASSES OF THERAPEUTIC AGENTS
por: Steer, A., et al.
Publicado: (2022)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2021)

Kinome expression profiling to target new therapeutic avenues in multiple myeloma
por: de Boussac, Hugues, et al.
Publicado: (2020)

Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
por: Vikova, Veronika, et al.
Publicado: (2019)

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
por: Ovejero, Sara, et al.
Publicado: (2022)

RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
por: Viziteu, E, et al.
Publicado: (2017)

Comprehensive characterization of the epigenetic landscape in Multiple Myeloma
por: Alaterre, Elina, et al.
Publicado: (2022)

Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact
por: Devin, Julie, et al.
Publicado: (2019)

RECQ helicases are deregulated in hematological malignancies in association with a prognostic value
por: Viziteu, Elena, et al.
Publicado: (2016)

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
por: Herviou, Laurie, et al.
Publicado: (2018)

Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors
por: Malek, Ehsan, et al.
Publicado: (2016)

A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy
por: Kassambara, Alboukadel, et al.
Publicado: (2014)

Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma
por: Gourzones, Claire, et al.
Publicado: (2019)

Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma Cells
por: Gourzones, Claire, et al.
Publicado: (2019)

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
por: Bruyer, Angelique, et al.
Publicado: (2018)

Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell
por: Kassambara, Alboukadel, et al.
Publicado: (2017)

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
por: Caraux, Anouk, et al.
Publicado: (2012)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
por: Acosta-Alvear, Diego, et al.
Publicado: (2015)

Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
por: Moreaux, J, et al.
Publicado: (2013)

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
por: Qiang, Ya-Wei, et al.
Publicado: (2018)

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
por: Bennett, Melissa K., et al.
Publicado: (2021)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Acquisition of a Multidrug Resistant Phenotype with a Proteasome Inhibitor in Multiple Myeloma
por: Gutman, Delia, et al.
Publicado: (2009)

Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020)

P844: GLOBAL CHARACTERIZATION OF MONOCYTE REVEALS A STRESS SIGNATURE INDUCED BY MULTIPLE MYELOMA BY SINGLE-CELL RNA SEQUENCING
por: Cui, Jian, et al.
Publicado: (2023)

Tetrahydrobiopterin induces proteasome inhibitor resistance and tumor progression in multiple myeloma
por: Zhang, Hua, et al.
Publicado: (2022)

Metabolic Alterations in Multiple Myeloma: From Oncogenesis to Proteasome Inhibitor Resistance
por: Weir, Philip, et al.
Publicado: (2023)

Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
por: Sharma, Aditi, et al.
Publicado: (2022)

Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma
por: Herviou, Laurie, et al.
Publicado: (2021)

Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
por: Rossi, J-F, et al.
Publicado: (2009)

Deregulation of Cell Death in Cancer: Recent Highlights
por: Carafa, Vincenzo, et al.
Publicado: (2020)

The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma
por: Maneix, Laure, et al.
Publicado: (2021)

Drug metabolism and clearance system in tumor cells of patients with multiple myeloma
por: Hassen, Wafa, et al.
Publicado: (2014)

Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma
por: Kassambara, Alboukadel, et al.
Publicado: (2012)

Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma
por: Farrell, Mariah L., et al.
Publicado: (2018)

Highlighting the Proteasome: Using Fluorescence to Visualize Proteasome Activity and Distribution
por: Gan, Jin, et al.
Publicado: (2019)

A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma
por: Mitra, A K, et al.
Publicado: (2017)

Is foot deformity associated with developmental dysplasia of the hip?: results after examination of 60,844 newborns
por: Håberg, Øvind, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dtpiik9d4e02lls26hl1mthvsm